CD268, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD268, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD268, Human |
| Clone | REA1115 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | fluorescein (FITC) conjugate |
| Size | 100 tests in 200 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD268 Antibody, anti-human, FITC, REAfinity™. Clone REA1115 recognizes the human CD268 antigen, also known as B cell-activating factor receptor (BAFF-R), or BAFF receptor 3 (BR3). It is a 19 kDa type III transmembrane protein which belongs to the TNF receptor superfamily and is mainly expressed on B cells. BAFF-R plays an important role in B cell differentiation and promotes survival and activation of B cells. | Additional information: Clone REA1115 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | TNFRSF13c, BR3, BAFFR, BROMIX, CVID4, prolixin, BAFF-R |
| Gene, Accession # | Gene ID: 115650 |
| Catalog # | 130-119-296 |
| Price | $275 |
| Order / More Info | CD268, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Thompson, J. S. et al. (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293 (5537): 2108-2111. | Kayagaki, N. et al. (2002) BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 17 (4): 515-524. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies